{"filing":{"accession_number":"0001193125-26-338013","cik":"0001812364","ticker":"RLAY","company_name":"Relay Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"rlay-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-20260806.htm"},"events":[{"id":25624,"run_id":23257,"accession_number":"0001193125-26-338013","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million, allowing the company to sell an additional $213 million in shares through an unregistered equity program.","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26507,"accession_number":"0001193125-26-338013","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million. The company has already sold $163 million under the original agreement and is now authorized to sell an additional $213 million in shares through an ATM program. This is a material dilutive equity issuance under Rule 415(a)(4) of the Securities Act, representing a significant expansion of the company's ability to raise capital through unregistered equity sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:06.560594+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25625,"run_id":23257,"accession_number":"0001193125-26-338013","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Relay Therapeutics announced second quarter 2026 financial results on August 6, 2026, reporting revenue of $0.4 million, R\u0026D expenses of $76.5 million, G\u0026A expenses of $14.7 million, a net loss of $83.7 million ($0.41 per share), and a cash position of $911 million, along with clinical progress updates.","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26508,"accession_number":"0001193125-26-338013","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Relay Therapeutics' second quarter 2026 financial results announced on August 6, 2026. The press release (Exhibit 99.2) reports Q2 2026 results including revenue of $0.4 million, R\u0026D expenses of $76.5 million, G\u0026A expenses of $14.7 million, and a net loss of $83.7 million ($0.41 per share), along with cash position of $911 million and clinical progress updates on zovegalisib programs. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:06.560594+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26507,"accession_number":"0001193125-26-338013","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million. The company has already sold $163 million under the original agreement and is now authorized to sell an additional $213 million in shares through an ATM program. This is a material dilutive equity issuance under Rule 415(a)(4) of the Securities Act, representing a significant expansion of the company's ability to raise capital through unregistered equity sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:06.560594+00:00","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-08-06"},{"id":26508,"accession_number":"0001193125-26-338013","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Relay Therapeutics' second quarter 2026 financial results announced on August 6, 2026. The press release (Exhibit 99.2) reports Q2 2026 results including revenue of $0.4 million, R\u0026D expenses of $76.5 million, G\u0026A expenses of $14.7 million, and a net loss of $83.7 million ($0.41 per share), along with cash position of $911 million and clinical progress updates on zovegalisib programs. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:06.560594+00:00","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-08-06"}]}